Cutting the cost of South African antiretroviral therapy using newer, safer drugs.

Abstract

Antiretrovirals are a significant cost driver for HIV programmes. Current first-line regimens have performed well in real-life programmes, but have a low barrier to virological resistance and still carry toxicity that limits adherence. New drug developments may mean that we have access to safer, more robust and cheaper regimens, but only if the appropriate… (More)
DOI: 10.7196/SAMJ.2016.v107.i1.12058

Topics

3 Figures and Tables

Slides referencing similar topics